---
title: "Vraylar (cariprazine) in major depressive disorder: Safety questions"
description: "Safety questions on Vraylar (cariprazine) in major depressive disorder, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects, Safety management, and Warnings. Questions: What are the most common side effects of Vraylar for depression? Does Vraylar cause weight gain when added to an antidepressant? Does Vraylar raise blood sugar or cholesterol? Does Vraylar raise prolactin levels in depression trials? 6 further questions follow. 10 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/vraylar--major-depressive-disorder/safety"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Vraylar (cariprazine) in major depressive disorder: Safety questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Vraylar](https://www.rxabbvie.com/pdf/vraylar_pi.pdf)

Safety questions that apply to every indication of Vraylar are on [Vraylar (cariprazine), all indications: Safety](https://www.evicenter.com/medical-information/vraylar/safety).

## Side effects

<a id="vraylar-common-side-effects"></a>

### What are the most common side effects of Vraylar for depression?

> “Most common adverse reactions in two 6-week MDD studies (≥5% and at least twice that of placebo)<sup>1</sup>
>  	Placebo + ADT (n=503)	VRAYLAR 1.5 mg/day + ADT (n=502)	VRAYLAR 3 mg/day + ADT (n=503)
> Insomnia<sup>||</sup>	5%	9%	10%
> Nausea	3%	7%	6%
> Akathisia<sup>¶</sup>	2%	7%	10%”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Tolerability and Safety, captured 2026-11-13](https://www.vraylarhcp.com/safety/adult-safety#:~:text=Most%20common%20adverse%20reactions%20in,10%25)

> “Adjunctive Treatment of Major Depressive Disorder:
> In 6-week, fixed-dose trials the incidences within the recommended doses (VRAYLAR 1.5 mg/day + antidepressant therapy [ADT] or 3 mg/day + ADT vs placebo + ADT) were akathisia (7%, 10% vs 2%), nausea (7%, 6% vs 3%), and insomnia (9%, 10% vs 5%).
> In one 8-week flexible-dose trial, incidences within the doses (VRAYLAR 1-2 mg/day + antidepressant therapy [ADT] or 2-4.5 mg/day + ADT vs placebo + ADT) were akathisia (8%, 23% vs 3%), restlessness (8%, 8% vs 3%), fatigue (7%, 10% vs 4%), constipation (2%, 5% vs 2%), nausea (7%, 13% vs 5%), increased appetite (2%, 5% vs 2%), dizziness (4%, 5% vs 2%), insomnia (14%, 16% vs 8%), and extrapyramidal symptoms (12%, 18% vs 5%).”

Source: [VRAYLAR: VRAYLAR® (cariprazine) for major depressive disorder (aMDD), captured 2026-11-13](https://www.vraylarhcp.com/indication-overview/amdd#:~:text=Adjunctive%20Treatment%20of%20Major%20Depressive,symptoms%20%2812%25%2C%2018%25%20vs%205%25%29.)

> “In clinical trials, dosage and titration at intervals of less than 14 days resulted in a higher incidence of adverse reactions.”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Dosing Information, captured 2026-11-13](https://www.vraylarhcp.com/dosing#:~:text=In%20clinical%20trials%2C%20dosage%20and,higher%20incidence%20of%20adverse%20reactions.)

Note: The 2-4.5 mg/day arm of the 8-week trial extends above the 3 mg/day maximum recommended dosage for MDD.

<a id="vraylar-weight-gain"></a>

### Does Vraylar cause weight gain when added to an antidepressant?

> “In 6-week MDD studies, VRAYLAR + ADT-treated patients demonstrated mean weight change of 1.5 lb<sup>1</sup>
>  	Mean changeat endpoint	Proportion of patients withweight increase ≥7%
> Placebo + ADT (n=503)	+0.4 lb	1%
> VRAYLAR 1.5 mg/day+ ADT (n=502)	+1.5 lb	2%
> VRAYLAR 3 mg/day+ ADT (n=503)	+1.5 lb	2%”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Tolerability and Safety, captured 2026-11-13](https://www.vraylarhcp.com/safety/adult-safety#:~:text=In%206%2Dweek%20MDD%20studies%2C%20VRAYLAR,2%25)

> “In the 8-week study, mean weight change was <2 lb in patients treated with VRAYLAR + antidepressant<sup>1</sup>*”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Tolerability and Safety, captured 2026-11-13](https://www.vraylarhcp.com/safety/adult-safety#:~:text=In%20the%208%2Dweek%20study%2C%20mean,in%20patients%20treated%20with%20VRAYLAR)

> “*In the 8-week MDD study, 2.5% of people taking VRAYLAR + ADT had a weight increase of ≥7% vs 2% of those taking placebo. The mean weight changes reported in this study were VRAYLAR 1-2 mg/day + ADT (n=273) = +1.98 lb; VRAYLAR 2-4.5 mg/day + ADT (n=273) = +1.98 lb; placebo + ADT (n=266) = 0 lb.<sup>1</sup>”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Tolerability and Safety, captured 2026-11-13](https://www.vraylarhcp.com/safety/adult-safety#:~:text=%2AIn%20the%208%2Dweek%20MDD%20study%2C,%2B%20ADT%20%28n%3D266%29%20%3D%200)

> “Weight Gain: Weight gain has been observed with VRAYLAR. Monitor weight at baseline and frequently thereafter.”

Source: [VRAYLAR: VRAYLAR® (cariprazine) for major depressive disorder (aMDD), captured 2026-11-13](https://www.vraylarhcp.com/indication-overview/amdd#:~:text=Weight%20Gain%3A%20Weight%20gain%20has,at%20baseline%20and%20frequently%20thereafter.)

<a id="vraylar-metabolic-effects"></a>

### Does Vraylar raise blood sugar or cholesterol?

> “Metabolic Changes: Atypical antipsychotics, including VRAYLAR, have caused metabolic changes, such as:”

Source: [VRAYLAR: VRAYLAR® (cariprazine) for major depressive disorder (aMDD), captured 2026-11-13](https://www.vraylarhcp.com/indication-overview/amdd#:~:text=Metabolic%20Changes%3A%20Atypical%20antipsychotics%2C%20including%20VRAYLAR%2C%20have%20caused%20metabolic%20changes%2C%20such%20as%3A)

> “Hyperglycemia and Diabetes Mellitus: Hyperglycemia, in some cases associated with ketoacidosis, hyperosmolar coma, or death, has been reported in patients treated with atypical antipsychotics. Assess fasting glucose before or soon after initiation of treatment, and monitor periodically during long-term treatment.
> Dyslipidemia: Atypical antipsychotics cause adverse alterations in lipids. Before or soon after starting an antipsychotic, obtain baseline fasting lipid profile and monitor periodically during treatment.”

Source: [VRAYLAR: VRAYLAR® (cariprazine) for major depressive disorder (aMDD), captured 2026-11-13](https://www.vraylarhcp.com/indication-overview/amdd#:~:text=Hyperglycemia%20and%20Diabetes%20Mellitus%3A%20Hyperglycemia%2C,and%20monitor%20periodically%20during%20treatment.)

> “In 6-week MDD studies, VRAYLAR demonstrated metabolic shifts similar to placebo for total cholesterol and fasting triglycerides when taken with an antidepressant<sup>1,2</sup>
>
> Total cholesterol	Proportion of patients with metabolicshifts was similar to placebo<sup>†</sup>
> Fasting triglycerides
> Fasting glucose	97% of patients did not have a clinicallymeaningful increase in blood glucose<sup>‡</sup>”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Tolerability and Safety, captured 2026-11-13](https://www.vraylarhcp.com/safety/adult-safety#:~:text=In%206%2Dweek%20MDD%20studies%2C%20VRAYLAR%20demonstrated,increase%20in%20blood)

> “<sup>†</sup>In the 6- and 8-week MDD studies, proportion of patients with metabolic shifts was similar to placebo. Shift defined as: total cholesterol: normal/borderline (<240 mg/dL) to high (≥240 mg/dL); fasting triglycerides: normal/borderline (<200 mg/dL) to high (≥200 mg/dL).<sup>1</sup>
>
> <sup>‡</sup>In the 6-week studies, the proportion of patients with shifts in fasting glucose from normal (<100 mg/dL) to high (≥126 mg/dL): VRAYLAR 1.5 mg/day + ADT=2%; VRAYLAR 3 mg/day + ADT=3.2%; placebo-treated=1.3%. The proportion of patients with shifts in fasting glucose from normal to borderline (≥100 and <126 mg/dL) or from borderline to high was similar in patients treated with VRAYLAR and placebo. In the 8-week study, the shifts in fasting glucose were similar among the VRAYLAR and placebo + ADT groups.<sup>1</sup>”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Tolerability and Safety, captured 2026-11-13](https://www.vraylarhcp.com/safety/adult-safety#:~:text=the%206%2D%20and%208%2Dweek%20MDD,VRAYLAR%20and%20placebo%20%2B%20ADT)

<a id="vraylar-prolactin"></a>

### Does Vraylar raise prolactin levels in depression trials?

> “Prolactin (ng/mL)<sup>§</sup>	No meaningful increase in mean levels”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Tolerability and Safety, captured 2026-11-13](https://www.vraylarhcp.com/safety/adult-safety#:~:text=Prolactin,meaningful%20increase%20in%20mean%20levels)

> “<sup>§</sup>In two 6-week MDD studies, mean change from baseline in prolactin levels was 4.1 ng/mL and 3.8 ng/mL in the 1.5 mg/day + ADT group (baseline mean: 9.4 - 9.7) and 2.6 ng/mL and 2.9 ng/mL in the 3 mg/day group + ADT (baseline mean: 11.3 - 11.6) vs 1.2 ng/mL and 0.92 ng/mL in the placebo + ADT group (baseline mean: 9.7 - 10.5). In the 8-week MDD study, the mean change from baseline was 3.8 ng/mL in the 1-2 mg/day + ADT group (baseline mean: 8.8) and 4.1 ng/mL in the 2-4.5 mg/day + ADT group (baseline mean 9.4) vs 0.7 ng/mL in the placebo group (baseline mean: 9.4).<sup>2</sup>”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Tolerability and Safety, captured 2026-11-13](https://www.vraylarhcp.com/safety/adult-safety#:~:text=two%206%2Dweek%20MDD%20studies%2C%20mean,the%20placebo%20group%20%28baseline%20mean%3A)

<a id="vraylar-akathisia"></a>

### How common is akathisia with Vraylar for depression?

> “Akathisia<sup>¶</sup>	2%	7%	10%”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Tolerability and Safety, captured 2026-11-13](https://www.vraylarhcp.com/safety/adult-safety#:~:text=2%25-,7%25,10%25)

> “<sup>¶</sup>Akathisia terms: akathisia, psychomotor hyperactivity, feeling jittery, nervousness, tension.”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Tolerability and Safety, captured 2026-11-13](https://www.vraylarhcp.com/safety/adult-safety#:~:text=terms%3A%20akathisia%2C%20psychomotor%20hyperactivity%2C%20feeling%20jittery%2C%20nervousness%2C%20tension.)

> “1.4% of VRAYLAR-treated patients discontinued treatment as a result of akathisia compared with 0.4% of placebo-treated patients<sup>2</sup>”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Tolerability and Safety, captured 2026-11-13](https://www.vraylarhcp.com/safety/adult-safety#:~:text=1.4%25%20of%20VRAYLAR%2Dtreated%20patients%20discontinued,compared%20with%200.4%25%20of%20placebo%2Dtreated)

Note: The percentages are for placebo + antidepressant, Vraylar 1.5 mg/day + antidepressant, and Vraylar 3 mg/day + antidepressant in two 6-week MDD studies, as in the table header on the safety page.

<a id="vraylar-somnolence"></a>

### Does Vraylar cause drowsiness or sedation in depression trials?

> “Rates of somnolence and sedation in VRAYLAR 1.5 mg/day + ADT (5%) and 3 mg/day + ADT (6%) groups were similar to placebo + ADT (4%).<sup>2</sup>”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Tolerability and Safety, captured 2026-11-13](https://www.vraylarhcp.com/safety/adult-safety#:~:text=Rates%20of%20somnolence%20and%20sedation,similar%20to%20placebo%20%2B%20ADT)

> “Potential for Cognitive and Motor Impairment: Somnolence was reported with VRAYLAR. Caution patients about performing activities requiring mental alertness (eg, operating hazardous machinery or a motor vehicle).”

Source: [VRAYLAR: VRAYLAR® (cariprazine) for major depressive disorder (aMDD), captured 2026-11-13](https://www.vraylarhcp.com/indication-overview/amdd#:~:text=Potential%20for%20Cognitive%20and%20Motor,machinery%20or%20a%20motor%20vehicle%29.)

<a id="vraylar-sexual-side-effects"></a>

### Does Vraylar cause sexual side effects in depression trials?

> “Less than 1% of VRAYLAR + ADT-treated patients reported sexual adverse reactions in two 6-week MDD studies<sup>2#</sup>
>  	Placebo + ADT (n=503)	VRAYLAR 1.5 mg/day + ADT (n=502)	VRAYLAR 3 mg/day + ADT (n=503)
> Abnormal orgasm	0%	0%	0.2%
> Decreased libido	0%	0.2%	0%
> Erectile dysfunction	0%	0.2%	0%
> Ejaculation failure	0%	0.2%	0%
> Ejaculation disorder	0%	0%	0%
>
> <sup>#</sup>These are self-reported adverse effects. If an adverse effect was not reported during a study, a value of 0 was used.”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Tolerability and Safety, captured 2026-11-13](https://www.vraylarhcp.com/safety/adult-safety#:~:text=Less%20than%201%25%20of%20VRAYLAR,value%20of%200%20was%20used.)

<a id="vraylar-discontinuation-rates"></a>

### How many patients stopped Vraylar because of side effects in depression trials?

> “In two 6-week MDD studies, 4% of VRAYLAR-treated patients discontinued treatment compared with 2% of placebo-treated patients when following recommended titration schedule.”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Tolerability and Safety, captured 2026-11-13](https://www.vraylarhcp.com/safety/adult-safety#:~:text=In%20two%206%2Dweek%20MDD%20studies%2C%204%25,when%20following%20recommended%20titration%20schedule.)

> “There were no adverse reactions leading to discontinuation that occurred at a rate of ≥2% in VRAYLAR patients and at least twice the rate of placebo.”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Tolerability and Safety, captured 2026-11-13](https://www.vraylarhcp.com/safety/adult-safety#:~:text=There%20were%20no%20adverse%20reactions,twice%20the%20rate%20of%20placebo.)

## Safety management

<a id="vraylar-akathisia-management"></a>

### How was akathisia from Vraylar managed in the depression trials?

> “Additional akathisia data from 6-week adjunctive MDD studies<sup>2</sup>
>
> Level of severity
>
> 94% of akathisia events were mild or moderate in patients treated with VRAYLAR + ADT in the two 6-week MDD studies
>
> Management
>
> In patients who experienced akathisia, rescue medications were used by approximately 3% of patients taking VRAYLAR + ADT and by 0.4% of patients taking placebo + ADT**
>
> Resolution
>
> Akathisia resolved, on average, within approximately 2 weeks for patients receiving VRAYLAR + ADT<sup>††</sup>
>
> **The most common rescue medication used was propranolol.<sup>2</sup>
>
> <sup>††</sup>The discontinuation rates due to akathisia reported in these studies were placebo + ADT (n=503) = 0.4%; VRAYLAR 1.5 mg/day + ADT (n=502) = 0.6%; VRAYLAR 3 mg/day + ADT (n=503) = 2.2%; VRAYLAR Overall + ADT (n=1005) = 1.4%.<sup>2</sup>”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Tolerability and Safety, captured 2026-11-13](https://www.vraylarhcp.com/safety/adult-safety#:~:text=Additional%20akathisia%20data%20from%206%2Dweek,VRAYLAR%20Overall%20%2B%20ADT%20%28n%3D1005%29)

On the page, select: Additional akathisia data

## Warnings

<a id="vraylar-tardive-dyskinesia"></a>

### Can Vraylar cause tardive dyskinesia?

> “1 out of 1,551 patients taking VRAYLAR + ADT in adjunctive MDD trials experienced tardive dyskinesia<sup>‡‡</sup>
>
> In two fixed-dose 6-week and one flexible-dose 8-week placebo-controlled adjunctive MDD trials
>
> 8 out of 7,431 patients taking VRAYLAR experienced tardive dyskinesia<sup>§§</sup>
>
> In 21 clinical trials, across 4 clinical development programs for VRAYLAR indications, ranging from 3 to 72 weeks<sup>‖‖</sup>”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Tolerability and Safety, captured 2026-11-13](https://www.vraylarhcp.com/safety/adult-safety#:~:text=1%20out%20of%201%2C551%20patients,ranging%20from%203%20to%2072)

On the page, select: Tardive dyskinesia data

> “Risk of developing tardive dyskinesia (a syndrome of potentially irreversible, involuntary, dyskinetic movements) and the likelihood it will become irreversible may increase with the duration of treatment and the cumulative dose. The syndrome can develop after a relatively brief treatment period, even at low doses, or after treatment discontinuation. If signs and symptoms of tardive dyskinesia appear, drug discontinuation should be considered.<sup>1</sup>”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Tolerability and Safety, captured 2026-11-13](https://www.vraylarhcp.com/safety/adult-safety#:~:text=Risk%20of%20developing%20tardive%20dyskinesia,appear%2C%20drug%20discontinuation%20should%20be)

On the page, select: Tardive dyskinesia data

> “<sup>‡‡</sup>Dosing ranged from 1.5 mg–4.5 mg/day.<sup>2</sup>
>
> <sup>§§</sup>Dosing ranged from 1.5 mg–12 mg/day.<sup>2</sup>”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Tolerability and Safety, captured 2026-11-13](https://www.vraylarhcp.com/safety/adult-safety#:~:text=ranged%20from%201.5%20mg%E2%80%934.5,ranged%20from%201.5%20mg%E2%80%9312)

On the page, select: Tardive dyskinesia data

Note: The second figure (8 of 7,431 patients) counts 21 trials across all four Vraylar development programs, including bipolar I disorder and schizophrenia.

## Related pages
- [Medical information: Vraylar (cariprazine): Major depressive disorder](https://www.evicenter.com/medical-information/vraylar--major-depressive-disorder)
- [Indication](https://www.evicenter.com/medical-information/vraylar--major-depressive-disorder/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/vraylar--major-depressive-disorder/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/vraylar--major-depressive-disorder/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/vraylar--major-depressive-disorder/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/vraylar--major-depressive-disorder/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/vraylar--major-depressive-disorder/access-and-coverage)
